Cargando…
Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins
Autores principales: | Dwojak, M, Bobrowicz, M, Bil, J, Bojarczuk, K, Pyrzynska, B, Siernicka, M, Malenda, A, Lech-Maranda, E, Tomczak, W, Giannopoulos, K, Golab, J, Winiarska, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450327/ https://www.ncbi.nlm.nih.gov/pubmed/25860291 http://dx.doi.org/10.1038/bcj.2015.27 |
Ejemplares similares
-
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy
por: Pyrzynska, Beata, et al.
Publicado: (2018) -
Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies
por: Winiarska, Magdalena, et al.
Publicado: (2014) -
Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020) -
B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin A nephropathy or vasculitis with nephritis
por: Lundberg, Sigrid, et al.
Publicado: (2017) -
Case Report: Ofatumumab treatment in a patient with rituximab-intolerant refractory autoimmune GFAP astrocytopathy
por: Cao, Shugang, et al.
Publicado: (2023)